重组人脑利钠肽治疗急性心力衰竭近期疗效及安全性观察  

Recombinant human brain natriuretic peptide in the treatment of acute heart failure curative effect and safety

作　　者：吕长泳[1] 朱成朔[1] 王立旗[1] 曹莉芳[1] Lv Changyong;Zhu Chengshuo;Wang Liqi;Cao Lifang(second people's Hospital of Cardiology,Kaifeng,Henan Kaifeng 475002)

机构地区：[1]开封市第二人民医院心内科,开封475002

出　　处：《北方药学》2018年第4期149-150,共2页Journal of North Pharmacy

摘　　要：目的:观察重组人脑利钠肽/新活素(rhBNP)治疗急性心力衰竭(AHF)的近期疗效及安全性。方法:将急性心力衰竭患者73例,随机分为治疗组36例和对照组37例,治疗组在标准治疗的基础上加用重组人脑利钠肽,对照组给予标准心力衰竭治疗。观察治疗前后两组临床症状、相关心衰指标及安全性。结果:两组治疗后临床症状均有改善,治疗组总有效率为94.44%,显著高于对照组的75.68%(P<0.05);治疗组治疗后左室射血分数(LVEF)和左室舒张期E峰/A峰比值(E/A)均较治疗前及对照组显著增加(P均<0.05);NT-proBNP较治疗前及对照组均显著降低(P<0.05),两组安全指标比较无明显差异(P>0.05)。结论:重组人脑利钠肽治疗严重急性心力衰竭安全有效。Objective:to study the effects of recombinant human brain natriuretic peptide/new live(rhBNP)in the treatment of acute heart failure(AHF)efficacy and safety.Methods:73 patients with acute heart failure,randomly assigned 36 patients in the treatment group and the control group in 37 cases,treatment groups based on the standard treatment combined with recombinant human brain natriuretic peptide,the control group received standard heart failure therapy.Before and after treatment,two sets of clinical symptoms,related changes in indicators of heart failure and safety indicators.Results:clinical symptoms have improved after treatment,which the effective rate in the treatment group is 94.44%,significantly higher than the control group 75.68%(P<0.05)Treatment group after the treatment of left ventricular ejection fraction(LVEF)and left ventricular diastolic peak(P约0.05)treatment after treatment of left ventricular ejection fraction(LVEF)and left ventricular diastolic peak(P<0.05),No significant difference in patient safety indicators between the two groups(P跃0.05).Conclusion:Recombinant human brain natriuretic peptide in the treatment of severe acute heart failure is safe and effective.

关 键 词：重组人脑利钠肽 N末端B型利钠肽 急性心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]